Guidance, NICE advice and quality standards In development
Showing 301 to 307 of 307
| Title | Type | Expected publication date |
|---|---|---|
| VTS-270 for treating Niemann-Pick type C1 [ID1267] | Highly specialised technology | TBC |
| Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance | |
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392] | Technology appraisal guidance | TBC |
| Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085] | Technology appraisal guidance | |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | |
| Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123] | Technology appraisal guidance |